Montelukast treatment in children with moderately severe atopic dermatitis

European Annals of Allergy and Clinical Immunology

Volumn 39, Issue 7, 2007, Pages 232-236

  Ehlayel, M S ^a   Bener, A ^a,b   Sabbah, A ^c  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NONE   (France)

Author keywords

Atopic dermatitis; Children; Moderate severe; Montelukast

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; MONTELUKAST; PLACEBO; STEROID;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG USE; EOSINOPHIL COUNT; FEMALE; HUMAN; MALE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP DISORDER; TREATMENT RESPONSE;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; EOSINOPHILS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; MALE; QUINOLINES; SLEEP; TREATMENT OUTCOME;

EID: 37549015243     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abramovits W. - Atopic dermatitis. J Am Acad Dermatol 2005;53:S86-S93.
2. Cookson W. - The genetics of atopic dermatitis: Strategies, candidate genes, and genome screens. J Am Acad Dermatol 2001;45:S7-9.
3. Purvis D.-J., Thompson JMD., Clark P.-M., Robinson E., Black P.-N., Wild C.-J. et al. - Risk factors for atopic dermatitis in New Zealand children at 3-5years of age. Br J Dermatol 2005;152:742-749.
4. Emerson R.-M., Charman C.-R., Williams H.-C. - The Nottingham eczema severity score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol 2000;142:p. 288-97.
5. Emerson R.-M., Williams H.-C., Allen B.-R. - Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998;139:73-6.
6. Dhar S. - Grading of severity of atopic dermatitis in north Indian children. Indian J Dermatol 1995;40:67-72.
7. Grad O., Hsu C, Sung J., Nisha S. - Impact of atopic dermatitis treatment on quality of life: results from findings in atopic children with eczema (FACE) study. J Am Acad Dermatol 2004;50:P248.
8. Kupczyk M, Kuna P. [The role of leukotrienes in inflammation and leukotriene inhibitors] [Article in Polish]. Pol Merkuriusz Lek, 1999;7:85-93.
9. Dhar S., Biseswar M., Rajib M., Apurba G., Amulya G. Correlation of the severity of atopic dermatitis with growth retardation in pediatric age group. Indian J Dermatol 2005 50:125-8.
10. Brehler R., Hildebrand A. and Luger T. - Recent developments in the treatment of atopic eczema. J Am Acad Dermatol 1997;36(6):983-94.
11. Lane J.-E., Jason M., Cheney J.-M., Lane T.-N., Kent D.-E., Cohen D.-J. - Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68-72.
12. Hanifin J.-M., Rajka G. - Diagnostic features of atopic dermatitis. Acta Dermatol Venereol Suppl (Stockh) 1980;92:44-7.
13. Consensus report of the European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:p.23-31.
14. Simpson E.-L., Hanifin J.-M. - Atopic dermatitis. J Am Acad Dermatol 2005;53:115-28.
15. Rackal J.-M., Vender R.-B. - The treatment of atopic dermatitis and other dermatosis with leukotriene antagonists. Skin Therapy Lett 2004;9:1-5.
16. Chari S., Clark-Loeser L., Shupack J., Washenik K. - A role for leukotriene antagonists in atopic dermatitis? Am J Clin Dermatol 2001;2:1-6.
17. Yanase D.-J., David-Bajar K. - The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001;44:89-93.
18. Capella G.-L., Grigerio E., Altomare G.- A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001;11:209-13.
19. Eustachio N., Pannofino A., Fanelli M., Ferrannini A., Tursi A. - Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol 2002;82:297-8.
20. Angelova-Fischer I., Tsankov N. - Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Dermatoven APA 2005;14:115-9.
21. Pei A.-Y., Chan H.-H., Leung T.-F. - Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001;12:154-8.
22. Silverberg N.-B., Paller A.-S. - Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. J Am Acad Dermatol 2004;50:485-6.
23. Chonca del Rio L.-E., Arroyave C.-M. - A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients. Am J Clin Dermatol 2003;2:p.1-6.
24. Dhar S., Malakar R., Chattopadhyay S., Dhar S., Banerjee R., Ghosh A. - Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels. Indian J Dermatol Venereol Leprol 2005;71:246-9.
25. Laske N., Niggemann B. - Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol 2004;15:86-8.
26. Schauer U., Trube M., Jager R., Gieler U., Rieger G.-H. - Blood eosinophil, eosinophil-derived protein, and leukotrienes C4 generation in relation to bronchial hyperreactivity in children with atopic dermatitis. Allergy 1995;50:126-32.
27. Shimizu T., Kristjansson S., Wennergren G., Strannegard I.-L., Strandvik B. - Leukotriene B4 and C4 generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with dermatitis. Pediatr Allergy Immunol 1994;5 95-9.